Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of B&B Bro & Betong

November 16, 2023 Real Estate and Construction M&A

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of B&B Bro & Betong Projektledning AB (”B&B Bro & Betong”).

B&B Bro & Betong is a consulting company that offers qualified project and construction management services within infrastructure and urban development. The services include several stages of the construction process such as feasibility studies, investigations, system documents, construction documents, production and handover, and the company works actively with continuous improvements and follows ISO requirements for quality and environmental management. B&B Bro & Betong participates in many of Mälardalen’s major societally important infrastructure projects and clients include the City of Stockholm, Ports of Stockholm, the Swedish Transport Administration and the new metro.

Vinge's team consisted of partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Egil Svensson, Sara Passandideh and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025